AMPHAmphastar Pharmaceuticals, Inc.
- Analyst Upgrades
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20
Piper Sandler analyst David Amsellem maintains Amphastar Pharma with a Neutral and lowers the price target from $21 to $20. ...
- Analyst Upgrades
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma with a Equal-Weight and raises the price target from $19 to $20. ...
- Earnings Call Transcripts
Amphastar Pharmaceuticals, Inc. - Second Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INC
Greetings and welcome to the Amphistar Pharmaceuticals, Inc. Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If any ...
- Earnings Call Transcripts
Second Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INC
Greetings and welcome to the Amphistar Pharmaceuticals, Inc. Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If any ...
- PR Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and... ...
- PR Newswire
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30,... ...
- CNBC
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear. ...
- Analyst Upgrades
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page. ...
- Analyst Upgrades
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20
B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma from Neutral to Underperform and lowers the price target from $25 to $20. ...
- US FDA
FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. This action aligns with President Trump’s Great American Recovery Initiative, a federal effort to address the U.S.’ addiction and substance use disorder crisis and coordinate the government's approach to prevention, treatment, and long-term recovery. “Reducing opioid overdose deaths is a top priority for FDA,” said Mike Davis M.D., Ph.D.,... ...
- Analyst Upgrades
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20
Barclays analyst Glen Santangelo maintains Amphastar Pharma with a Equal-Weight and lowers the price target from $23 to $20. ...
- AccessWire
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at ...
- Analyst Upgrades
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19
Wells Fargo analyst Benjamin Burnett downgrades Amphastar Pharma from Overweight to Equal-Weight and lowers the price target from $30 to $19. ...
- Earnings Call Transcripts
2026 GLOBAL HEALTHCARE CONFERENCEAMPHASTAR PHARMACEUTICALS INC
All right, everybody. We're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech at B of A, and I'm pleased to be intro ...
- Analyst Upgrades
Piper Sandler Reiterates Neutral on Amphastar Pharma, Lowers Price Target to $21
Piper Sandler analyst David Amsellem reiterates Amphastar Pharma with a Neutral and lowers the price target from $25 to $21. ...
- Analyst Upgrades
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See what analysts think about HUBS stock. ...
- Analyst Upgrades
Needham Downgrades Amphastar Pharma to Hold
Needham analyst Serge Belanger downgrades Amphastar Pharma from Buy to Hold. ...
- AccessWire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Net revenues of $171.2 million for the three months ended March 31, 2026GAAP net income of $6.4 million, or $0.14 per share, for the first quarterAdjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the ...
- AccessWire
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be ...
- AccessWire
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the ...
- Analyst Upgrades
Jefferies Downgrades Amphastar Pharma to Hold, Lowers Price Target to $22
Jefferies analyst Dennis Ding downgrades Amphastar Pharma from Buy to Hold and lowers the price target from $30 to $22. ...
- Analyst Upgrades
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $23
Barclays analyst Glen Santangelo maintains Amphastar Pharma with a Equal-Weight and lowers the price target from $30 to $23. ...
- AccessWire
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and ...
- Analyst Upgrades
Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $30
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma with a Overweight and lowers the price target from $34 to $30. ...
- Analyst Upgrades
Needham Maintains Buy on Amphastar Pharma, Lowers Price Target to $30
Needham analyst Serge Belanger maintains Amphastar Pharma with a Buy and lowers the price target from $34 to $30. ...